Cargando…

Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice

OBJECTIVE: A prophylactic vaccine is needed to control the HCV epidemic, with genotypes 1–3 causing >80% of worldwide infections. Vaccine development is hampered by HCV heterogeneity, viral escape including protection of conserved neutralising epitopes and suboptimal efficacy of HCV cell culture...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alzua, Garazi Pena, Pihl, Anne Finne, Offersgaard, Anna, Duarte Hernandez, Carlos Rene, Duan, Zhe, Feng, Shan, Fahnøe, Ulrik, Sølund, Christina, Weis, Nina, Law, Mansun, Prentoe, Jannick C, Christensen, Jan Pravsgaard, Bukh, Jens, Gottwein, Judith Margarete
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933178/ https://www.ncbi.nlm.nih.gov/pubmed/35918103 http://dx.doi.org/10.1136/gutjnl-2021-326323

Ejemplares similares

Identification of novel neutralizing determinants for protection against HCV
por: Alzua, Garazi P., et al.
Publicado: (2023)

Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency
por: Czarnota, Anna, et al.
Publicado: (2020)

High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals
por: Pihl, Anne F., et al.
Publicado: (2018)

HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice
por: Prentoe, Jannick, et al.
Publicado: (2016)

Novel HCV Genotype 4d Infectious Systems and Assessment of Direct-Acting Antivirals and Antibody Neutralization
por: Pham, Long V., et al.
Publicado: (2022)

Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine
por: Lothert, Keven, et al.
Publicado: (2020)

HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4
por: Pham, Long V., et al.
Publicado: (2022)

An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals
por: Offersgaard, Anna, et al.
Publicado: (2023)

Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A
por: Velázquez-Moctezuma, Rodrigo, et al.
Publicado: (2017)

Effect of Glycan Shift on Antibodies against Hepatitis C Virus E2 412–425 Epitope Elicited by Chimeric sHBsAg-Based Virus-Like Particles
por: Czarnota, Anna, et al.
Publicado: (2023)

SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor
por: Offersgaard, Anna, et al.
Publicado: (2021)

Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro
por: Zhou, Yuyong, et al.
Publicado: (2021)

The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design
por: von Delft, Annette, et al.
Publicado: (2016)

High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor
por: Offersgaard, Anna, et al.
Publicado: (2022)

Genetic and structural insights into broad neutralization of hepatitis C virus by human V(H)1-69 antibodies
por: Tzarum, Netanel, et al.
Publicado: (2019)

Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19
por: Underwood, Alexander P., et al.
Publicado: (2021)

Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies
por: Bankwitz, Dorothea, et al.
Publicado: (2021)

Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry
por: Prentoe, Jannick, et al.
Publicado: (2018)

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants
por: Jensen, Sanne Brun, et al.
Publicado: (2019)

Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination
por: Underwood, Alexander P., et al.
Publicado: (2023)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Economic study of the value of expanding HCV treatment capacity in Germany
por: Sbarigia, Urbano, et al.
Publicado: (2017)

Analysis of Functional Differences between Hepatitis C Virus NS5A of Genotypes 1–7 in Infectious Cell Culture Systems
por: Scheel, Troels K. H., et al.
Publicado: (2012)

Host cell mTORC1 is required for HCV RNA replication
por: Stöhr, Stefanie, et al.
Publicado: (2016)

Defining the key intrahepatic gene networks in HCV infection driven by sex
por: Marchi, Emanuele, et al.
Publicado: (2023)

An alternate conformation of HCV E2 neutralizing face as an additional vaccine target
por: Tzarum, Netanel, et al.
Publicado: (2020)

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
por: Gammeltoft, Karen Anbro, et al.
Publicado: (2023)

Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection
por: Fitzmaurice, Karen, et al.
Publicado: (2015)

Hyperbilirubinaemia in HIV–HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?
por: Kaspar, Matthew B, et al.
Publicado: (2016)

Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes
por: Manousou, Pinelopi, et al.
Publicado: (2014)

Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection
por: Keng, Choong Tat, et al.
Publicado: (2016)

Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape
por: Colpitts, Che C, et al.
Publicado: (2018)

Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux
por: Crouchet, Emilie, et al.
Publicado: (2017)

Novel host genetic variations associated with spontaneous clearance of a single-source outbreak of HCV1b infections
por: You, Hong, et al.
Publicado: (2015)

Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein
por: Sautto, Giuseppe A, et al.
Publicado: (2016)

Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators
por: Van, Nguyen Dinh, et al.
Publicado: (2016)

Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication
por: Ramirez, Santseharay, et al.
Publicado: (2021)

Remaining challenges in HCV elimination
por: Capraru, Camelia, et al.
Publicado: (2021)

miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis
por: Van Renne, Nicolaas, et al.
Publicado: (2018)

Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity
por: Augestad, Elias H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_32checrs6up9mm67hdbuep20oa